These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 7319478)

  • 21. Genetically abnormal fibrinogens--strategies for structure elucidation, including fibrinopeptide analysis.
    Henschen A; Kehl M; Southan C
    Curr Probl Clin Biochem; 1984; 14():273-320. PubMed ID: 6391842
    [No Abstract]   [Full Text] [Related]  

  • 22. Direct analysis of plasma fibrinogen-derived fibrinopeptides by high performance liquid chromatography: investigation of A alpha-chain N-terminal heterogeneity.
    Southan C; Thompson E; Lane DA
    Thromb Haemost; 1986 Oct; 56(2):193-7. PubMed ID: 3643663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purification and primary structures of duck fibrinopeptides A and B.
    Yuan M; Zhu P; Zhang YS
    Sci Sin B; 1985 Jan; 28(1):31-5. PubMed ID: 3983613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in the measurement of circulating fibrinogen derivatives.
    Wilner GD
    Prog Clin Pathol; 1984; 9():15-45. PubMed ID: 6229812
    [No Abstract]   [Full Text] [Related]  

  • 25. Regulation of fibrinogen biosynthesis: effect of fibrin degradation products, low-molecular-weight peptides of fibrinogenolysis, and fibrinopeptides A and B.
    Kessler CM; Bell WR
    J Lab Clin Med; 1979 May; 93(5):758-67. PubMed ID: 429874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion of fibrinogen to fibrin induced by preferential release of fibrinopeptide B.
    Dyr JE; Blombäck B; Hessel B; Kornalík F
    Biochim Biophys Acta; 1989 Jan; 990(1):18-24. PubMed ID: 2914147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Coagulation-fibrinolysis abnormalities in acute stage hypertensive intra-cerebral hemorrhage and head injury (preliminary report). With special reference to fibrinopeptides A and B beta 15-42].
    Touho H; Hino A; Suzuki K; Kubo S; Hirakawa K
    Neurol Med Chir (Tokyo); 1985 Mar; 25(3):203-8. PubMed ID: 2409465
    [No Abstract]   [Full Text] [Related]  

  • 28. Kinetic characterization of inhibition of human thrombin with DNA aptamers by turbidimetric assay.
    Zavyalova EG; Protopopova AD; Yaminsky IV; Kopylov AM
    Anal Biochem; 2012 Feb; 421(1):234-9. PubMed ID: 22056408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Thrombin-fibrinogen interaction: release of fibrinopeptides and the effects of ATP].
    Gurrieri MA
    Medicina (Firenze); 1990; 10(1):51-2. PubMed ID: 2381284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening method for the addition of bovine blood-based binding agents to food using liquid chromatography triple quadrupole mass spectrometry.
    Grundy HH; Reece P; Sykes MD; Clough JA; Audsley N; Stones R
    Rapid Commun Mass Spectrom; 2007; 21(18):2919-25. PubMed ID: 17676711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Plasma fibrinopeptide A and fibrinopeptide B beta 15-42 levels in patients with Behçet's disease].
    Sunakawa M; Arai I; Okinami S
    Nippon Ganka Gakkai Zasshi; 1986 Jun; 90(6):871-4. PubMed ID: 3751789
    [No Abstract]   [Full Text] [Related]  

  • 32. Structural considerations of plasmic degradation of fibrinogen.
    Marder VJ; Budzynski AZ
    Pathol Biol (Paris); 1974 Nov; 22 suppl():43-6. PubMed ID: 4283397
    [No Abstract]   [Full Text] [Related]  

  • 33. [Coagulation-fibrinolysis abnormalities in acute stage of subarachnoid hemorrhage (Part 1)--With special reference to the relation between cerebral vasospasm and fibrinopeptides A and B beta].
    Touho H; Hino A; Suzuki K; Kubo T; Hirakawa K
    No To Shinkei; 1984 Oct; 36(10):1009-14. PubMed ID: 6518124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinogen Aarhus--a new case of dysfibrinogenemia.
    Hessel B; Stenbjerg S; Dyr J; Kudryk B; Therkildsen L; Blombäck B
    Thromb Res; 1986 Apr; 42(1):21-37. PubMed ID: 2939591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of fibrinogen/fibrin degradation products (F/F DP)].
    Alakhverdian R
    Vutr Boles; 1979; 18(3):160-7. PubMed ID: 89851
    [No Abstract]   [Full Text] [Related]  

  • 36. Purification of human fibrinopeptides by high-performance liquid chromatography.
    Koehn JA; Canfield RE
    Anal Biochem; 1981 Sep; 116(2):349-56. PubMed ID: 7316166
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical significance of fibrinopeptide A and B beta 15-42 analysis in blood coagulo-fibrinolytic tests].
    Koshihara K; Fuzimaki M
    Nihon Rinsho; 1989 Dec; 48 Suppl():889-91. PubMed ID: 2622023
    [No Abstract]   [Full Text] [Related]  

  • 38. Determination of fibrinopeptide A by high performance liquid chromatography and its significance.
    Mao P; Wang BM; Shen D; Wei WN
    Chin Med J (Engl); 1988 May; 101(5):353-6. PubMed ID: 3145836
    [No Abstract]   [Full Text] [Related]  

  • 39. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
    Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
    Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unique pattern of fibrinogen cleavage by human leukocyte proteases.
    Bilezikian SB; Nossel HL
    Blood; 1977 Jul; 50(1):21-8. PubMed ID: 871524
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.